NRGene, RCK Partner to Develop Medical Cannabis DNA Biomarkers

Sep 04, 2018

|

NEW YORK (GenomeWeb) — NRGene said today that it has partnered with Israeli cannabis production company RCK to develop DNA-based biomarkers for medical cannabis breeding and strain identification.

Under the terms of the deal, the partners will use NRGene's computational tools to develop the biomarkers for commercial use. Additional terms were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Scan

Australia's Gene Editing Policy Approach

Australia will not be regulating gene editing of plants, animals, and human cell lines as long as no new genetic material is incorporated, reports Nature News.

Just "Preliminary" Work

The Washington Post reports that the US Department of Agriculture told its researchers to label peer-reviewed articles as "preliminary" work.

Some Big Trees

Researchers have sequenced the genomes of both the coast redwood and the giant sequoia, according to the San Francisco Chronicle.

This Week in PNAS

In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.

Featured White Papers

BlueBee Data Security & Compliance

Whole Genome Sequencing of Microbial Communities for Scaling Microbiome and Metagenomic Studies

NGS is Accelerating Therapeutic Antibody Discovery - What Lies Beyond?

Powerful Bioinformatic Support for Specialized Therapeutic Antibody Discovery

May

07

Featured Webinar

Implementing a Multisite Clinical System for Genomics with Best-in-Class Tools: the GenoVic Project

This webinar will discuss the implementation of an enterprise-wide clinical genomics platform that is shared across 10 hospitals and research organizations in the Australian State of Victoria.

Jun

17

Featured Webinar

Personal and Clinical Utility of Polygenic Risk Scores: A Review of the Evidence

This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.

Menu